GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NightHawk Biosciences Inc (LTS:0A4E) » Definitions » EV-to-Revenue

NightHawk Biosciences (LTS:0A4E) EV-to-Revenue : 1.71 (As of Jun. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is NightHawk Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NightHawk Biosciences's enterprise value is $16.67 Mil. NightHawk Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $9.74 Mil. Therefore, NightHawk Biosciences's EV-to-Revenue for today is 1.71.

The historical rank and industry rank for NightHawk Biosciences's EV-to-Revenue or its related term are showing as below:

LTS:0A4E' s EV-to-Revenue Range Over the Past 10 Years
Min: -540.05   Med: 6.8   Max: 7561.62
Current: 1.78

During the past 13 years, the highest EV-to-Revenue of NightHawk Biosciences was 7561.62. The lowest was -540.05. And the median was 6.80.

LTS:0A4E's EV-to-Revenue is ranked better than
81.07% of 1030 companies
in the Biotechnology industry
Industry Median: 7.73 vs LTS:0A4E: 1.78

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-24), NightHawk Biosciences's stock price is $6.72917. NightHawk Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.37. Therefore, NightHawk Biosciences's PS Ratio for today is 17.99.


NightHawk Biosciences EV-to-Revenue Historical Data

The historical data trend for NightHawk Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NightHawk Biosciences EV-to-Revenue Chart

NightHawk Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 3.54 - -28.53 2.87

NightHawk Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 5.42 8.05 2.87 1.69

Competitive Comparison of NightHawk Biosciences's EV-to-Revenue

For the Biotechnology subindustry, NightHawk Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NightHawk Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NightHawk Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where NightHawk Biosciences's EV-to-Revenue falls into.



NightHawk Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

NightHawk Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16.670/9.743
=1.71

NightHawk Biosciences's current Enterprise Value is $16.67 Mil.
NightHawk Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NightHawk Biosciences  (LTS:0A4E) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

NightHawk Biosciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.72917/0.374
=17.99

NightHawk Biosciences's share price for today is $6.72917.
NightHawk Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NightHawk Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of NightHawk Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NightHawk Biosciences (LTS:0A4E) Business Description

Traded in Other Exchanges
Address
627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560
NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.

NightHawk Biosciences (LTS:0A4E) Headlines

No Headlines